Search for: "MERCK SHARP "
Results 101 - 120
of 266
Sorted by Relevance
|
Sort by Date
21 Jun 2021, 1:18 pm
The Supreme Court discussed in Wyeth and later clarified in Merck Sharp & Dohme Corp. v. [read post]
19 Feb 2014, 6:57 am
• GlaxoSmithKline LLC • Merck Sharp & Dohme Corporation • Mylan Pharmaceuticals Inc. [read post]
19 Mar 2012, 4:16 am
Judge Birss QC assures us that his decision in Merck Sharp Dohme Corp & Anor v Teva Pharma BV & Anor [2012] EWHC 627 (Pat), relating to an application by Bristol-Myers Squibb for an interim injunction pending trial, raises no issue of principle, but he does provide an enlightening discussion of how to address some issues of fact that are common in an application for a quia timet injunction, including a review of the European case law. [read post]
7 Mar 2024, 12:00 am
On 18 January 2024, in case C-367/21 (still no English version) the CJEU ruled again on the exhaustion of EU trade mark rights (following its five rulings of 17 November 2022 including C-175/21 Harman International Industries, C-224/20 Merck Sharp & Dohme, and C‑204/20 Bayer Intellectual Property). [read post]
8 Nov 2018, 1:06 am
Ilarion TomarovThe Ukrainian Supreme Court in Merck Sharp & Dohme Corp v Aurobindo Pharma Limited has recently introduce a bold approach to applying interim injunctions in disputes between originators and generics over the registration of patented pharmaceuticals. [read post]
7 Jan 2013, 2:16 am
See Merck Sharp & Dohme Corp. v. [read post]
10 Jan 2019, 10:00 pm
Below is a brief summary of issues before the Court last week: Merck Sharp & Dohme Corp. v. [read post]
13 May 2011, 3:20 pm
Inc., Merck Sharp & Dohme BV, and Merck Sharp & Dohme and Paranova Danmark A/S and Paranova Pack A/S v Merck Sharp & Dohme Corp., Merck Sharp & Dohme and Merck Sharp & Dohme BV is only available on the Curia website in a random selection of official European Union languages that does not include Maltese, Bulgarian or English, but the IPKat wouldn't like to think that any dispute… [read post]
30 Mar 2022, 7:01 pm
The case is noteworthy because it contains a cogent and well-reasoned exploration of many of the issues flowing from the Supreme Court’s decision in Merck Sharp & Dohme Corp. v. [read post]
7 Jan 2019, 3:58 am
The first is Merck Sharp & Dohme v. [read post]
27 Apr 2015, 8:58 am
Merck Sharp & Dohme Corp., 2015 U.S. [read post]
16 Feb 2012, 1:33 pm
According to the Merck Manual, peripheral neuropathy is “dysfunction of one or more peripheral nerves. [read post]
25 Jun 2019, 2:00 am
Merck Sharp & Dohme Corp. may leave stakeholders in the pharmaceutical space scratching their heads, and highlights that it’s rarely possible to anticipate and avoid every claim construction issue that may be raised in a patent challenge. [read post]
22 Jun 2010, 9:36 am
Only yesterday the IPKat reported on Case C-207/10 Paranova Danmark A/S, Paranova Pack A/S v Merck Sharp & Dohme Corp. [read post]
11 Oct 2018, 12:57 am
Eszter SzakácsCo-author: Zsolt Lengyel, Danubia Patent and Law Office Just a few months before the CJEU’s judgment in C-121/17 Teva UK Ltd and Others v Gilead Sciences Inc. came out a the Metropolitan Court of Budapest handed down a decision regarding Merck Sharp and Dohme Corp’s (MSD) application for an SPC re the combination of ezetimibe and rosuvastatin. [read post]
7 Mar 2010, 8:04 pm
The Australian judge found “that Merck Sharpe & Dohme failed in its duty of care by not warning Peterson's doctor about the drug's potential cardiovascular risk, and by its sales representatives emphasizing the drug's safety. [read post]
12 Feb 2021, 7:11 am
The device includes a sheath defining a distal surface for placement on the skin of the subject, a movable handle, a sensor support, and two sharp supports. [read post]
12 Mar 2021, 6:33 am
In this week’s featured patent applications, we cover the latest from ExxonMobil, Roche, Boston Scientific, Abbott, Medtronic, Merck, Paypal, Intel, Apple, IBM, and Microsoft. [read post]
21 Jun 2013, 6:17 am
Merck, Sharp & Dohme Corp., U.S., No. 12-1318, cert. petition denied 6/3/13). [read post]
17 May 2016, 10:11 am
This moggy will be speaking about enablement and sufficiency, in particular looking at the "plausibility" criterion that has become increasingly prominent in recent UK cases, for example Generics v Warner Lambert and Merck Sharp & Dohme v Ono Pharmaceutical. [read post]
